PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced a significant milestone in the development of ... Read More
Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD
Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for PTG-300 for polycythemia vera treatment. Polycythemia vera ... Read More